Stability Testing in Pharma Manufacturing: What Actually Determines Shelf Life

Stability testing sounds like a formality until you've seen what happens without it: a batch of antibiotics loses potency six months before its printed expiry because nobody validated the formulation against humidity exposure in the actual climate zone it ships to. Pakistan and much of South Asia fall under ICH Climatic Zone IVb, hot and very humid, which is a meaningfully harsher storage condition than the temperate zones many international stability protocols were originally built around.

What stability testing actually measures. At its core, it's tracking how a drug product's potency, degradation products, dissolution rate, and physical characteristics change over time under controlled temperature and humidity. Accelerated testing runs samples at 40 degrees C and 75% relative humidity for six months to predict long-term behavior quickly. Long-term testing runs at 30 degrees C / 65% RH (the Zone IVb condition) for the full proposed shelf life, sometimes 24 or 36 months, generating the real data that supports the label claim.

The two data sets rarely tell identical stories, and that's the point. A formulation can look stable under accelerated conditions and still show a slow, real-time degradation curve that only shows up at month 18 of long-term testing. Relying on accelerated data alone to set a shelf-life claim is a shortcut regulators have gotten much stricter about catching, particularly for generics filed through DRAP or seeking export registration.

Dissolution testing deserves its own mention because it's the parameter most likely to drift without anyone noticing until a complaint comes in. A tablet can hold its assay value (the amount of active ingredient present) perfectly while its dissolution profile, how fast that ingredient actually releases into solution, slows down as the excipients age or the coating changes. For a fast-acting analgesic or an antihypertensive where onset timing matters clinically, a slowed dissolution profile is a real efficacy problem even though the tablet still contains the correct dose on paper.

Photostability testing under ICH Q1B catches a different failure mode: active ingredients that degrade under light exposure during normal pharmacy shelf display or patient home storage, not just in a dark warehouse. Amber packaging isn't decorative, it's often the only thing standing between a light-sensitive molecule and a degraded batch three months after it leaves the manufacturer.

Where manufacturers actually cut corners, usually without meaning to: running stability studies on a pilot batch rather than the actual commercial-scale batch, since scale-up can change particle size distribution and moisture content in ways that affect degradation rate. Or testing fewer time points than the protocol calls for and interpolating between them, which produces a shelf-life claim built on statistical smoothing rather than measured data. Auditors from DRAP, and certainly from stricter export markets like the EU's EMA framework, ask for the raw time-point data, not just the summary curve.

Container closure system testing gets overlooked too. The stability of a tablet in a blister pack with a specific foil laminate is not the stability of that same tablet in a different packaging configuration. Changing a packaging supplier without re-running at least a bridging stability study is a common gap that shows up during export dossier review.

For manufacturers building an export dossier, the practical sequence that avoids rework: run accelerated stability alongside long-term studies from day one rather than waiting on accelerated results before starting long-term (they take a full two to three years to complete, so any delay in starting pushes the whole registration timeline back). Test the actual commercial batch and packaging configuration. And build in photostability and, where relevant, in-use stability testing (what happens after a multi-dose vial or bottle is opened) before a regulator asks for it rather than after.

Tti's pharma testing lab runs full ICH-compliant stability protocols, dissolution profiling, and photostability studies for manufacturers building both domestic and export-ready product dossiers, with chambers validated for Zone IVb conditions specifically.